A Phase 1b Experimental Pain Trial of Karuna-Xanomeline-Trospium (KarXT) in Healthy Volunteers
Latest Information Update: 06 Nov 2023
At a glance
- Drugs Trospium chloride/xanomeline (Primary)
- Indications Pain
- Focus Adverse reactions
- Sponsors Karuna Therapeutics
Most Recent Events
- 02 Nov 2023 According to a Karuna Therapeutics media release, topline data expected in the fourth quarter of 2023.
- 03 Aug 2020 According to a Karuna Therapeutics media release, topline results of this exploratory trial were inconclusive and do not provide sufficient evidence of an analgesic benefit of KarXT compared to placebo. The Company will not move forward to develop KarXT in pain.
- 03 Aug 2020 According to a Karuna Therapeutics media release, the company will continue to evaluate data from this trial to better assess the potential role of muscarinic-targeted receptor treatments in pain management.